EBMT-EHA CAR-T 2019 | CAR T-cell therapy: AML adverse events and optimization

Elizabeth Budde

Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, discusses the toxicities associated with CAR T-cell therapy in the treatment of acute myeloid leukemia and what optimization is needed in the manufacuring of CAR T-cell products. Dr Budde was speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

Share this video